Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bromhexine + guaifenesin is an oral fixed-dose combination of the mucolytic agent bromhexine and the expectorant guaifenesin, used for the symptomatic treatment of productive (chesty) cough and respiratory conditions characterized by excessive, viscous mucus such as acute and chronic bronchitis and other bronchopulmonary disorders.[2][3][8][9] Bromhexine depolymerizes and thins mucopolysaccharide fibers in bronchial secretions, reducing mucus viscosity and facilitating ciliary clearance, while guaifenesin increases the volume and decreases the adhesiveness and surface tension of bronchial secretions, making mucus easier to mobilize and expectorate.[2][3][4][9] Together, this small‑molecule combination enhances mucociliary clearance and converts unproductive cough into a more productive one without opioid-induced sedation, and is marketed in multiple countries in various over-the-counter and prescription cough and cold products, particularly as syrups and oral liquids.[2][3][8][9]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bromhexine + guaifenesin.